Acute Myelogenous Lymphoma (AML)

First (CR1)/Second (CR2) Remission
- **BMT302**: Phase II ibrutinib Maintenance After Reduced-Intensity Conditioning & Allogeneic HCT in Acute Leukemia
  - PI: Rezvani Stanford

Advanced Disease
- Matched Related or Unrelated Donor
  - **BMT342**: Phase II/III to Identify Novel Intervention to Alleviate Morbidity & Mortality After Allogeneic HCT
    - PI: Johnston Pending
  - **BMT36**: Phase I/II MAHCT w/ T-Cell Depleted Graft + Conventional & Regulatory T Cells in Advanced Hematologic Malignancies
    - PI: Meyer Pending

First (CR1) or Higher Remission
- Matched Related or Unrelated Donor
  - **BMT340**: Phase III Tacrolimus/Methotrexate vs Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in PBSCT
    - PI: Rezvani, Meyer NIH
  - **BMT338**: Phase I DonorGrafts Derived From OrcaGraft w/GVHD Prophylaxis in MA-alloHCT in Hematologic Malignancies
    - PI: Meyer Orca Biosytems

- Matched Related Donor

**KEY**
- Pending
- Open for Enrollment
- Observational Study
- Link
- Optional Path
- Trial Posting
- Extension Study
- Immunotherapy

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu